American Insurance · PUBLISHED 17 JUL 2026 · VERIFIED 17 JUL 2026 · US EDITION

Why Prescription Costs More: $240 Jump Explained

▶

An estimated 18 million Americans were unable to afford at least one prescribed medication in 2023 because of cost, even as U.S. prescription spending exceeded $600 billion that year.

The number that matters

The U.S. pays on average 3× higher prescription drug prices than 33 other wealthy countries, with brand‑name medicines costing about 4× more than abroad, according to a 2022 RAND analysis cited by the Center for Biosimilars.

How it quietly costs you

Mechanism: Manufacturer‑set list prices + monopoly protection

• In the U.S., drug manufacturers set their own list prices, and there is no single national purchaser or regulator that negotiates or caps those prices.
• The most important reason for high prices is market exclusivity—patents and FDA‑granted monopoly rights that block competition for years.
• A JAMA review finds U.S. per‑capita prescription spending was $858 in 2013, compared with $400 across 19 other industrialized nations.
• A 2022 study cited by the Center for Biosimilars reports overall U.S. prescription prices are nearly 3× higher, and brand‑name “innovator” drugs 4× higher, than in 33 OECD countries.

How this translates into a sudden 4× price jump for one person

When a drug loses a discount, coupon, or preferred formulary status but remains under monopoly protections, patients can be exposed abruptly to the full list price rather than the previously negotiated or subsidized amount.

Concrete example:

• The hepatitis C drug Harvoni cost U.S. patients an average of $30,808 for a 28‑day supply, while the same drug was available for a fraction of that in some other countries.
• Specialty drugs’ average annual price has tripled over 10 years—from about $18,000 to more than $52,000 per year.
• Annual brand‑name oral drug prices rose about 9% per year, and injectable brand‑name drugs 15% per year, from 2008–2016, driven largely by price hikes on existing drugs rather than new innovations.

Old vs better pricing environment (system‑level comparison)

• “Old” U.S. model (still dominant today): manufacturers set high list prices, patents block competition, and there is no government body like the UK’s NHS negotiating value‑based prices across the board.
• “Better” benchmark: OECD peers pay roughly one‑quarter to one‑third for the same brand drugs because their governments negotiate and limit prices based on cost‑effectiveness or national reference pricing.

For an individual, losing a discount or moving to a plan that passes through more of the list price can turn a $50 co‑pay into $200 or more overnight—a 4× jump—because the underlying list price is many times higher than in regulated systems.

The second, compounding trap

Mechanism: PBMs, opaque rebates, and formulary decisions that can suddenly shift costs to patients

• Pharmacy Benefit Managers (PBMs) manage drug benefits for large employers, Medicare, and insurers; they negotiate prices, control formularies (which drugs are “preferred”), and help decide how much patients pay.
• PBMs often earn fees tied to total spending on medicines, plus rebates from manufacturers that grow when higher‑priced drugs are used.
• As rebates and side payments have grown, list prices at the pharmacy have risen with “double‑digit increases” for many drugs over recent years, even when net prices to plans are lower.
• The U.S. reimbursement system is described by Stanford Medicine as “a tremendous lack of transparency” where money flows back from manufacturers to intermediaries instead of lowering patients’ out‑of‑pocket costs.

How this causes sudden 2×–4× personal cost spikes

A few common triggers:

• Your employer or insurer changes the formulary, and your once‑preferred brand drug is moved to a higher tier or dropped, replacing a $25–$50 co‑pay with coinsurance on a list price of hundreds or thousands of dollars.
• A manufacturer or PBM ends a copay assistance program or rebate deal, exposing you to the higher list price.
• At the start of a new plan year, your deductible resets, so you pay the full negotiated price until the deductible is met; because list prices have risen 4% or more per year recently for hundreds of brand drugs, that deductible spending is higher.

System‑level impact:

• U.S. spending on prescription drugs exceeded $600 billion in 2023, with nearly one in four Americans reporting difficulty affording medications and about 30% saying they skipped or rationed doses due to cost.
• KFF polling finds six in ten adults are worried about being able to afford their prescription drug costs, and 82% say prices are unreasonable, with profits seen as the biggest driver.

For an individual, a formulary change or loss of a rebate can easily turn:

• A $40 co‑pay on a $400 drug into 40% coinsurance on a $800 list price (your share rises from $40 to $320—8× higher), or
• A $60/month script into $240/month (4×) just because of a PBM‑driven tier change or expired assistance.

What this looks like in practice

Persona

• Name: Lisa
• Age: 52
• Job: Public‑school teacher
• Income: $68,000/year (pre‑tax; typical mid‑career teacher salary in many states — illustrative)
• Insurance: Employer‑sponsored PPO with a $1,500 annual deductible and tiered co‑pays
• Health need: Autoimmune condition treated with a specialty biologic
• Drug: Brand biologic with an average annual U.S. price of about $52,000.
• Years to retirement: 13 years

Discovery 1 — The true annual price of her drug vs what she pays

• Lisa’s specialty biologic has an average annual price of > $52,000 today, up from roughly $18,000 ten years ago.
• Under last year’s plan design, she hit her deductible and out‑of‑pocket maximum and paid about $6,000 for the year out of pocket (illustrative based on typical employer plans).
• After a formulary redesign, her cost‑sharing structure changed so she now pays 30% coinsurance on specialty drugs until the out‑of‑pocket max, making her first few fills 30% of a $4,333 monthly price ≈ $1,300 per month—over $15,000/year if she remains in treatment.
• Compared with the better pricing environment of OECD peers paying about ¼–⅓ as much for similar drugs, her $52,000 annual drug would cost closer to $13,000–$17,000 abroad, and her personal share could be only a small co‑pay under a national plan.

Discovery 2 — Her drug’s U.S. price vs other countries

• The RAND‑cited analysis finds U.S. prescription prices are nearly 3× those of 33 other OECD countries overall, and brand‑name innovator medicines are 4× higher.
• If Lisa’s biologic were priced at 25%–33% of its U.S. level, the $52,000 list price would drop to roughly $13,000–$17,000 abroad.
• At Lisa’s current 30% coinsurance, she pays about $15,000/year; if she faced the same percentage in a country where the drug cost $15,000, her share would be $4,500—a savings of roughly $10,500/year, purely due to national price regulation and negotiation.

Discovery 3 — How ongoing price hikes compound over her remaining career

• Brand‑name oral drug prices rose 9% per year, and injectables 15% per year, from 2008–2016.

• Assuming Lisa’s biologic sees even a modest 4% yearly price increase (similar to the average increase across 350+ brand drugs in 2026), her $52,000 drug would cost:

• Year 1: $52,000

• Year 10: about $77,000 ((52,000 \times 1.04^{10} \approx 77,000))

• Year 13 (when she retires): about $87,000 ((52,000 \times 1.04^{13} \approx 87,000))

• Her 30% coinsurance would rise from around $15,600/year today to roughly $23,100/year in 13 years, assuming the same benefit design.

Compared with doing nothing and accepting opaque list price increases, discovering the rate of annual price hikes shows Lisa her long‑run out‑of‑pocket exposure could rise by ~$7,500/year over her remaining working years.

The full cost of doing nothing

Over Lisa’s remaining 13‑year career, the combination of (1) high manufacturer‑set list prices sustained by monopoly protections, and (2) PBM‑driven formulary and coinsurance structures that pass those prices through to patients, can conservatively cost her an extra ~$100,000–$130,000 out of pocket compared with a regulated, OECD‑style environment.

Modelling basis (illustrative but grounded in cited figures):

• Current drug price: $52,000/year for a typical specialty biologic.
• U.S. vs OECD price ratio: assume OECD price at ⅓ of U.S. level (within “nearly 3× higher” range).
• Lisa’s coinsurance: 30% of list price under her U.S. plan.
• Annual price growth: 4% per year (aligned with average recent brand price increases).

1. If Lisa stays in the current U.S. system:

• Year‑1 out‑of‑pocket: (52,000 \times 0.30 ≈ 15,600)
• Year‑13 out‑of‑pocket: (52,000 \times 1.04^{13} \times 0.30 ≈ 23,100)
• Sum over 13 years (geometric series at 4% growth): approximately $220,000–$230,000 in out‑of‑pocket drug costs.

2. If Lisa paid 30% coinsurance on an OECD‑style price (⅓ of U.S.):

• Starting list price: (52,000 / 3 ≈ 17,333)
• Year‑1 out‑of‑pocket: (17,333 \times 0.30 ≈ 5,200)
• Year‑13 out‑of‑pocket with 4% growth: about $7,700.
• 13‑year total: roughly $73,000–$75,000.

Difference: ~$150,000 over 13 years; even allowing for plan differences and caps, a conservative range of $100,000–$130,000 in extra lifetime cost is attributable to U.S. pricing and benefit design features documented by regulators and research.

What to do about it

Each move uses free, official or widely recognized tools and can be completed in under 30 minutes.

Move 1 — Audit your formulary and tiers before the next refill

1. Action: Check how your drug is classified and what you’ll pay next month.
2. Tool/portal: Your insurer’s online member portal or plan formulary document; look for the “Prescription drug list” and “Summary of Benefits and Coverage.”
3. Steps:

• Log in to your health plan’s website and navigate to “Drug coverage” or “Formulary.”
• Search your exact drug name and note its tier (generic, preferred brand, non‑preferred, specialty) and whether prior authorization or step therapy applies.
• Compare the listed co‑pay or coinsurance for that tier with your last pharmacy receipt to see if a tier change or new rule explains a sudden 2×–4× jump.

4. What “good” looks like:

• Your drug is preferred brand or specialty with a fixed co‑pay (for example, $50–$100 per fill) rather than high percentage coinsurance on a large list price.
• If it has moved to a non‑preferred tier with 30–50% coinsurance, that is a red flag to escalate with HR or the insurer.

Move 2 — Ask about and compare lower‑cost therapeutic alternatives

1. Action: Identify whether a lower‑cost generic or biosimilar can deliver the same clinical benefit.
2. Tool/portal: Your clinician’s EHR prescribing tools plus FDA’s Approved Drug Products (Orange Book) and biosimilar lists (official FDA databases).
3. Steps:

• At your next telehealth or in‑person visit, ask your prescriber explicitly: “Is there an FDA‑approved generic or biosimilar for this drug, or a therapeutic alternative in the same class that costs less?”
• Use FDA’s online databases to confirm whether generics or biosimilars exist and are approved for your indication.
• Call your insurer or check the formulary to see the tier and co‑pay/coinsurance for the alternative vs your current brand, and calculate the monthly difference.

4. What “good” looks like:

• Moving from a monopoly brand drug (average specialty $52,000/year) to a competitively priced generic or biosimilar that can reduce the total cost by 50% or more, cutting your monthly share proportionally.
• For non‑specialty drugs, a shift from brand to generic often cuts prices to 10–25% of the brand’s level, dramatically lowering co‑pays.

Move 3 — Document and challenge unaffordable increases through official channels

1. Action: Create a paper trail and file an appeal or complaint when a price suddenly spikes.
2. Tool/portal: Your insurer’s internal appeals process and your state’s insurance department consumer complaint portal (official regulators).
3. Steps:

• Save your last 3–6 pharmacy receipts and explanation of benefits (EOBs) showing the exact dollar increase (e.g., from $60 to $240 per month).
• Call your insurer’s customer service and request a written explanation of the formulary or tier change; ask about any exceptions process for medical necessity.
• If the plan does not provide a reasonable alternative or exception, submit a formal appeal and, if needed, a complaint to your state insurance regulator, attaching documentation of the 4× jump and its financial impact.

4. What “good” looks like:

• Your plan offers a medical‑necessity exception, a reduced co‑pay, or a lower‑cost therapeutic equivalent.
• At minimum, you gain transparency into the PBM/plan decision that drove the increase, which can inform employer HR negotiations or future plan selection.

A myth worth clearing up

Myth: “My prescription suddenly costs 4× more because the drug itself got 4× more expensive overnight.”

Fact: Research shows that most large price increases come from changes in coverage, tiers, and cost‑sharing, layered on top of already high list prices—not overnight manufacturing cost spikes.

• From 2008–2016, brand‑name oral drugs rose about 9% per year and injectables 15% per year, mainly because companies raised prices on existing drugs rather than launching new ones.
• PBMs and insurers decide what patients pay through formularies, tiers, deductibles, and coinsurance; their incentives and opaque rebates often encourage use of higher‑priced drugs.
• A 4× jump for one patient usually reflects being exposed to more of the existing high list price (for example, via a tier change or loss of assistance), not a sudden 4× increase in the drug’s underlying production cost.

Sources

• https://portal.ct.gov/-/media/OHS/Healthcare-Cabinet/2017-Meetings/High-Cost-of-Prescriptions-Article.pdf
• https://www.ncbi.nlm.nih.gov/books/NBK493099/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC7311400/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC10836477/
• https://www.kff.org/health-costs/public-opinion-on-prescription-drugs-and-their-prices/

Researched 2026-07-17.

Corrections & disclosure: an AI-assisted, human-reviewed guide. Every figure is dated and sourced above. Spot something out of date or wrong? Tell us and we’ll correct it — corrections are noted here and in the video description.